The debate over where to set strength limits for nicotine pouches in the UK has generated more heat than light, partly because the competing positions are often argued past each other. Those who oppose any strength cap argue that restricting nicotine availability undermines harm reduction by making products less satisfying for heavy smokers. Those who favour very low caps argue that higher-strength products carry unacceptable risk for new users, particularly young people. A 20mg cap represents a position that can be defended against both sets of objections with evidence — but its proponents often fail to make that case effectively.
The harm reduction argument for 20mg rests on the saturation curve for nicotine delivery. Most adult smokers using pouches to manage nicotine intake report satisfaction at or below the 20mg level. Above that threshold, the incremental satisfaction benefit diminishes while the potential for rapid dose escalation increases. A 20mg cap therefore retains the harm reduction utility of pouches for the majority of adult users who are the primary public health beneficiaries of the category while limiting the ceiling on doses that have less clear benefit and higher potential for problematic use.
The youth protection argument is more complicated because the evidence on whether high-strength products are disproportionately used by young people — relative to lower-strength options — is limited. What the evidence does suggest is that palatability and packaging, rather than strength, are the primary drivers of youth appeal. A strength cap that does not also address flavour and marketing is likely to be less effective at reducing youth uptake than its advocates claim.
The Nordic evidence is instructive here. Sweden and Norway have operated with de facto strength norms in the snus market for decades, with the market settling around strength levels that correspond roughly to the 20mg pouch equivalent. The sky did not fall. Youth use of snus remained manageable. Smoking rates declined. The experience does not translate perfectly to the UK pouch market, but it offers more than a theoretical argument.
What the 20mg advocates need to do is make this case more precisely rather than allowing the debate to be framed as harm reduction versus protection. The strength cap and harm reduction are compatible positions, and the evidence supports saying so directly.
